THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS CASCAIS, Portugal, Nov. 17, 2025 (GLOBE NEWSWIRE) — Pulsar Helium Inc. (AIM: PLSR, TSXV: PLSR, OTCQB: PSRHF) (“Pulsar” or the “Company”), a primary helium development company, is pleased to announce that Thomas Abraham-James, Pulsar’s CEO, and Dr. Peter Barry, the Company’s Scientific Helium-3 Advisor, will provide a live investor presentation via Investor Meet Company...

NEW ADDITIONAL SHARE BUY-BACK OF EUR 1 BILLION Regulated Information Paris, 17 November 2025, 8:00 a.m. Societe Generale announces today a new exceptional capital distribution in the form of an additional EUR 1 billion share buy-back programme. The Board of Directors approved the launch of a new additional share buy-back programme, for cancellation purpose, of EUR 1 billion. Societe Generale obtained all necessary authorisations1, including from the ECB. These acquisitions of shares will be executed in compliance with the Market Abuse Regulation (MAR). Societe Generale will start to repurchase its shares on 19 November 2025 at the earliest. Press contacts:Jean-Baptiste Froville_+33 1 58 98 68 00_ jean-baptiste.froville@socgen.com Fanny Rouby_+33 1 57 29 11 12_ fanny.rouby@socgen.com Societe Generale Societe Generale is a top tier European...

PRESS RELEASENovember 17, 2025JOSEP MARIA RECASENS APPOINTED CHIEF STRATEGY, PRODUCT & PROGRAM MANAGEMENT OFFICER Boulogne-Billancourt, France, November 17, 2025 – Renault Group announces the appointment of Josep Maria Recasens as Chief Strategy, Product & Program Management Officer (SPPM), effective immediately. This change is part of a drive to simplify the organisation in order to increase its agility and speed. Reporting to François Provost, CEO of Renault Group, and as a member of the Leadership Team, Josep Maria Recasens will be responsible for defining the strategy to maintain the Group’s positive momentum, guiding product choices for the coming years and coordinating the implementation to ensure the success of the future line-up. In addition to his new role, Recasens will remain CEO of the Iberian Peninsula countries....

TME Pharma announces receipt of agreements in principle to extend certain bond agreements Berlin, Germany, November 17, 2025, 08.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, announced today that certain holders of the bonds issued in May and August, 2025 have agreed in principle to extend the maturity of the bonds for a one year period.  These bond holders, Diede van den Ouden (CEO) and 2 members of the Supervisory Board, hold 29% of the regular bonds issued in May and August 2025 for a total face value amount of €718,946. TME Pharma will also discuss with other lenders who participated in the May and August 2025 bond issuance to try to procure similar extensions of their debt. TME Pharma believes now may...

Tokyo, Japan and Cambridge and London, UK, 17 November 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announced a focused restructuring designed to concentrate investment and resources on efficient platforms, programs and products with the greatest value creation potential. Alongside a focus on prioritized programs, Nxera intends to implement initiatives to reduce operating expenses to support Nxera’s 2030 vision of ≥JPY50 billion in net sales and an operating profit margin of ≥30%. Nxera will discuss plans for this focused restructuring at its R&D Day webcast to be held tomorrow – for details on how to register, please go to link. Key objectives of the restructuringR&D focus and program prioritization: Strategic emphasis on best-in-class opportunities where the biology of G protein-coupled receptor...

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with the Company’s transition to a fully integrated commercial organization it has appointed James M. O’Brien as its US-based Chief Financial Officer (CFO). Jim has extensive experience in all aspects of financial management and planning having spent the majority of his career with multi-national public and private companies in the life sciences, biotechnology, and pharmaceutical industries. Mesoblast CEO Dr Silviu Itescu said: “We are very pleased to have Jim join us at Mesoblast. His deep cross functional financial expertise and knowledge of US markets fills a key senior leadership position as we transition to a mature commercial organization....

Technip Energies to supply liquefied CO2 marine loading arms for phase 2 of the Northern Lights project in Norway©Ruben Soltvedt_Northern LightsTechnip Energies (PARIS:TE) Loading Systems has been awarded a contract to supply three fully electric marine loading arms for phase 2 of the Northern Lights CO2 transport and storage project in Øygarden, Norway. The loading solution will be installed at the new Northern Lights jetty and will consist of three marine loading arms fully qualified to transfer liquefied CO2. For this second phase, Technip Energies Loading Systems will deliver a fully electric design, a first-of-a-kind eliminating the use of hydraulics and setting a new industry benchmark in terms of operability, safety, and environmental performance. This contract builds on the successful delivery of the world’s first liquefied...

Sampo plc, stock exchange release, 17 November 2025 at 8:30 am EET Sampo plc’s share buybacks 14 November 2025 On 14 November 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  8,653 9.97 AQEU    84,226 9.97 CEUX  20,079 9.97 TQEX  125,135 9.97 XHELTOTAL 238,093 9.97  * rounded to two decimals                      On 5 November 2025, Sampo announced a share buyback programme of up to a maximum of EUR 150 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 6 November...

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)US FDA clearance now allows use of the ARC-EX® System both in clinics and homes ARC-EX is the first and only FDA-cleared technology demonstrated to improve hand strength and sensation in people with spinal cord injury Year to date, ARC-EX Systems have been purchased by more than 60 US clinicsEINDHOVEN, the Netherlands, Nov. 17, 2025 (GLOBE NEWSWIRE) — ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announced that it has received 510(k) clearance to expand the ARC-EX System indication for home use in the...

The share repurchase programme runs as from 26 February 2025 and up to and including 30 January 2026 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 2.25 billion, cf. Corporate Announcement No. 3/2025 of 26 February 2025. The share repurchase programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014, the so-called “Market Abuse Regulation”, and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 2,540,304 630.81 1,602,437,66610 November 2025 15,000 769.10 11,536,52411...